NCT05191290View on ClinicalTrials.gov

Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
ApheresisAnticoagulation
Interventions
DRUG

unfractionated heparin

standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis

DRUG

Sodium Citrate

8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis

Trial Locations (1)

1210

University Medical Center Ljubljana, Ljubljana

All Listed Sponsors
lead

University Medical Centre Ljubljana

OTHER